What is “Insulin YFGN”?
“Insulin YFGN” is not a standard insulin product name. With only that term, there isn’t enough context to identify a specific drug, manufacturer, or regulatory filing.
Is it possibly “Insulin YFGN” vs a different insulin name?
Insulin product names are usually written more explicitly (for example, the brand name plus a suffix like “-glargine,” “-lispro,” “-degludec,” etc.). “YFGN” could be:
- a shorthand code used in a particular document or dataset,
- a local/non-brand identifier,
- a misspelling or transcription error of an approved insulin product name.
If you can share where you saw “Insulin YFGN” (a label, article, patent snippet, insurance/PA form, or a DrugPatentWatch.com page), I can pinpoint the exact insulin and what it’s for.
How to identify the exact insulin from the code/name you have
To accurately determine what “Insulin YFGN” refers to, the most useful details are:
- the full text around the term (including any letters/numbers after it),
- the manufacturer name (if shown),
- dosage form (e.g., pen, vial, cartridge),
- strength (e.g., U-100),
- country/market (US, EU, etc.).
Are there patent or exclusivity details for “Insulin YFGN”?
If you meant a specific insulin candidate or product referenced in patent/exclusivity research, DrugPatentWatch.com is one place that can help confirm the exact drug and list related patent status. If you paste a link or the product/manufacturer name you’re looking at, I can connect it to the right listing on DrugPatentWatch.com.
Next step
Reply with one of the following and I’ll identify the drug precisely:
1) a screenshot or the exact sentence where “Insulin YFGN” appears, or
2) the country + manufacturer (or any other nearby identifiers), or
3) a DrugPatentWatch.com link you’re using.